Reuse of drugs in the treatment of COVID-19

Detalhes bibliográficos
Autor(a) principal: Neri, Alessandra Isabô
Data de Publicação: 2022
Outros Autores: Carneiro, Lílian Carla, Carneiro, Cristiene Costa, Moraes Filho, Aroldo Vieira de, Chen-Chen, Lee
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/28484
Resumo: After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then on, the need arises to search for treatments and prevention of the disease, through some existing drugs, such as Chloroquine, Hydroxychloroquine, Ivermectin and Azithromycin. Objective: The objective of this study is to discuss existing drugs used for the possible treatment of COVID-19, clarify their mechanisms of action and studies that prove their effectiveness or not. Methodology: The narrative review of the literature was based on a search in the Google Scholar, Capes, Scielo and PubMed journals databases published in the last 3 years, using the terms: “covid-19 drugs in vitro/in vivo”; "SARS-CoV-2"; “coronavirus”. Results: From the analysis of the articles, it can be noted that there is not enough evidence to prove the effectiveness of these drugs in the fight against COVID-19. The studies that showed results in combating SARS-CoV-2 were in vitro, in addition to being at higher doses than recommended for humans. Conclusion: Therefore, its therapeutic safety for the prevention and treatment of COVID-19 has not yet been clarified and determined, thus, its indiscriminate use can potentiate adverse effects.
id UNIFEI_c9ff838381076a5126a51d5a6d8bd3f8
oai_identifier_str oai:ojs.pkp.sfu.ca:article/28484
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Reuse of drugs in the treatment of COVID-19Reutilización de medicamentos en el tratamiento del COVID-19Reutilização de fármacos no tratamento da COVID-19CloroquinaHidroxicloroquinaIvermectinaAzitromicinaSARS-CoV-2.CloroquinaHidroxicloroquinaIvermectinaAzitromicinaSARS-CoV-2.ChloroquineHydroxychloroquineIvermectinAzithromycinSARS-CoV-2.After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then on, the need arises to search for treatments and prevention of the disease, through some existing drugs, such as Chloroquine, Hydroxychloroquine, Ivermectin and Azithromycin. Objective: The objective of this study is to discuss existing drugs used for the possible treatment of COVID-19, clarify their mechanisms of action and studies that prove their effectiveness or not. Methodology: The narrative review of the literature was based on a search in the Google Scholar, Capes, Scielo and PubMed journals databases published in the last 3 years, using the terms: “covid-19 drugs in vitro/in vivo”; "SARS-CoV-2"; “coronavirus”. Results: From the analysis of the articles, it can be noted that there is not enough evidence to prove the effectiveness of these drugs in the fight against COVID-19. The studies that showed results in combating SARS-CoV-2 were in vitro, in addition to being at higher doses than recommended for humans. Conclusion: Therefore, its therapeutic safety for the prevention and treatment of COVID-19 has not yet been clarified and determined, thus, its indiscriminate use can potentiate adverse effects.Tras un brote de neumonía atípica en la ciudad de Wuhan, China, hubo alertas epidemiológicas por el factor desconocido. El 7 de enero de 2020, científicos chinos aislaron una cepa de coronavirus, en la que se identificó el agente etiológico. Rápidamente se propagó por todo el mundo y, por ello, fue declarada pandemia el 11 de marzo de 2020. A partir de entonces, surge la necesidad de buscar tratamientos y prevención de la enfermedad, a través de algunos fármacos existentes, como la Cloroquina, Hidroxicloroquina, Ivermectina. y azitromicina. Objetivo: El objetivo de este estudio es discutir los medicamentos existentes utilizados para el posible tratamiento de la COVID-19, esclarecer sus mecanismos de acción y estudios que comprueben su eficacia o no. Metodología: La revisión narrativa de la literatura se basó en una búsqueda en las bases de datos de las revistas Google Scholar, Capes, Scielo y PubMed publicadas en los últimos 3 años, utilizando los términos: “covid-19 drogas in vitro/in vivo”; "SARS-CoV-2"; "coronavirus". Resultados: Del análisis de los artículos, se puede notar que no existe suficiente evidencia que demuestre la efectividad de estos medicamentos en la lucha contra el COVID-19. Los estudios que mostraron resultados en el combate al SARS-CoV-2 fueron in vitro, además de ser a dosis superiores a las recomendadas para humanos. Conclusión: Por lo tanto, aún no se ha esclarecido y determinado su seguridad terapéutica para la prevención y tratamiento de la COVID-19, por lo que su uso indiscriminado puede potenciar efectos adversos.Após surto de pneumonia atípica na cidade de Wuhan, na China, ocorreram alertas epidemiológicos devido ao fator desconhecido. Em 7 de janeiro de 2020, cientistas chineses isolaram uma cepa de coronavírus, na qual foi identificado o agente etiológico. Logo se espalhou rapidamente pelo mundo e, por isso, foi declarada pandemia em 11 de março de 2020. A partir de então, surge a necessidade de buscar por tratamentos e prevenção da doença, por meio de alguns fármacos já existentes, como a Cloroquina, Hidroxicloroquina, Ivermectina e Azitromicina. Objetivo: O objetivo deste estudo é discutir sobre os medicamentos já existentes utilizados para o possível tratamento da COVID-19, esclarecer seus mecanismos de ação e estudos que comprovam sua eficácia ou não. Metodologia: A revisão narrativa da literatura foi baseada na busca nas bases de dados Google Acadêmico, Periódicos Capes, Scielo e PubMed publicados nos últimos 3 anos, por meio dos termos: “medicamentos covid-19 in vitro/in vivo”; “sars-cov-2”; “coronavírus”. Resultados: A partir da análise dos artigos, pode-se notar que não existem evidências suficientes para comprovar eficácia desses medicamentos no combate a COVID-19. Os estudos que mostraram resultados no combate ao SARS-CoV-2 foram in vitro, além de estarem em doses mais elevadas do que o recomendado para humanos. Conclusão: Portanto, a sua segurança terapêutica para a prevenção e tratamento da COVID-19 ainda não foi esclarecida e determinada, assim, o seu uso indiscriminado pode potencializar os efeitos adversos.Research, Society and Development2022-04-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2848410.33448/rsd-v11i5.28484Research, Society and Development; Vol. 11 No. 5; e43311528484Research, Society and Development; Vol. 11 Núm. 5; e43311528484Research, Society and Development; v. 11 n. 5; e433115284842525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/28484/24720Copyright (c) 2022 Alessandra Isabô Neri; Lílian Carla Carneiro; Cristiene Costa Carneiro; Aroldo Vieira de Moraes Filho; Lee Chen-Chenhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessNeri, Alessandra Isabô Carneiro, Lílian CarlaCarneiro, Cristiene CostaMoraes Filho, Aroldo Vieira deChen-Chen, Lee2022-04-17T18:18:56Zoai:ojs.pkp.sfu.ca:article/28484Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:52.257472Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Reuse of drugs in the treatment of COVID-19
Reutilización de medicamentos en el tratamiento del COVID-19
Reutilização de fármacos no tratamento da COVID-19
title Reuse of drugs in the treatment of COVID-19
spellingShingle Reuse of drugs in the treatment of COVID-19
Neri, Alessandra Isabô
Cloroquina
Hidroxicloroquina
Ivermectina
Azitromicina
SARS-CoV-2.
Cloroquina
Hidroxicloroquina
Ivermectina
Azitromicina
SARS-CoV-2.
Chloroquine
Hydroxychloroquine
Ivermectin
Azithromycin
SARS-CoV-2.
title_short Reuse of drugs in the treatment of COVID-19
title_full Reuse of drugs in the treatment of COVID-19
title_fullStr Reuse of drugs in the treatment of COVID-19
title_full_unstemmed Reuse of drugs in the treatment of COVID-19
title_sort Reuse of drugs in the treatment of COVID-19
author Neri, Alessandra Isabô
author_facet Neri, Alessandra Isabô
Carneiro, Lílian Carla
Carneiro, Cristiene Costa
Moraes Filho, Aroldo Vieira de
Chen-Chen, Lee
author_role author
author2 Carneiro, Lílian Carla
Carneiro, Cristiene Costa
Moraes Filho, Aroldo Vieira de
Chen-Chen, Lee
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Neri, Alessandra Isabô
Carneiro, Lílian Carla
Carneiro, Cristiene Costa
Moraes Filho, Aroldo Vieira de
Chen-Chen, Lee
dc.subject.por.fl_str_mv Cloroquina
Hidroxicloroquina
Ivermectina
Azitromicina
SARS-CoV-2.
Cloroquina
Hidroxicloroquina
Ivermectina
Azitromicina
SARS-CoV-2.
Chloroquine
Hydroxychloroquine
Ivermectin
Azithromycin
SARS-CoV-2.
topic Cloroquina
Hidroxicloroquina
Ivermectina
Azitromicina
SARS-CoV-2.
Cloroquina
Hidroxicloroquina
Ivermectina
Azitromicina
SARS-CoV-2.
Chloroquine
Hydroxychloroquine
Ivermectin
Azithromycin
SARS-CoV-2.
description After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then on, the need arises to search for treatments and prevention of the disease, through some existing drugs, such as Chloroquine, Hydroxychloroquine, Ivermectin and Azithromycin. Objective: The objective of this study is to discuss existing drugs used for the possible treatment of COVID-19, clarify their mechanisms of action and studies that prove their effectiveness or not. Methodology: The narrative review of the literature was based on a search in the Google Scholar, Capes, Scielo and PubMed journals databases published in the last 3 years, using the terms: “covid-19 drugs in vitro/in vivo”; "SARS-CoV-2"; “coronavirus”. Results: From the analysis of the articles, it can be noted that there is not enough evidence to prove the effectiveness of these drugs in the fight against COVID-19. The studies that showed results in combating SARS-CoV-2 were in vitro, in addition to being at higher doses than recommended for humans. Conclusion: Therefore, its therapeutic safety for the prevention and treatment of COVID-19 has not yet been clarified and determined, thus, its indiscriminate use can potentiate adverse effects.
publishDate 2022
dc.date.none.fl_str_mv 2022-04-12
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/28484
10.33448/rsd-v11i5.28484
url https://rsdjournal.org/index.php/rsd/article/view/28484
identifier_str_mv 10.33448/rsd-v11i5.28484
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/28484/24720
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 5; e43311528484
Research, Society and Development; Vol. 11 Núm. 5; e43311528484
Research, Society and Development; v. 11 n. 5; e43311528484
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052709884395520